Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis
NCT03906344 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2019-04-08
Summary
Expanded access use of INCB052793 to treat a single patient with Myelofibrosis.
Interventions
- DRUG
-
INCB052793
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Michael Savona, MD · Vanderbilt University Medical Center
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
NCT07281781 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
NCT05229588 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)
NCT06122831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
CEP-701 (Lestaurtinib) in Myelofibrosis
NCT00668421 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
NCT00665067 ·Status: COMPLETED
-
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
NCT06240754 ·Status: RECRUITING ·Phase: PHASE2
-
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
NCT01793051 ·Status: COMPLETED ·Phase: PHASE2
-
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
NCT00099047 ·Status: COMPLETED ·Phase: PHASE2
-
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT00291694 ·Status: COMPLETED ·Phase: PHASE2
-
Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?
NCT01099917 ·Status: COMPLETED ·Phase: PHASE2
-
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
NCT06388759 ·Status: TERMINATED ·Phase: PHASE1
-
Quantitative MRI for Myelofibrosis
NCT01973881 ·Status: RECRUITING
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
NCT06063486 ·Status: RECRUITING ·Phase: PHASE2
-
Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
NCT06025851 ·Status: COMPLETED ·Phase: PHASE1
-
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
NCT04549363 ·Status: TERMINATED ·Phase: PHASE3
-
CEP-701 for PH-negative Myelofibrosis
NCT00494585 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
NCT01269203 ·Status: WITHDRAWN ·Phase: PHASE2
-
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
NCT07174427 ·Status: RECRUITING ·Phase: PHASE3
-
Allogeneic BM-MSCs in Patients with Lumbar Facet Arthropathy
NCT04410731 ·Status: COMPLETED ·Phase: PHASE1
-
Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease
NCT01711073 ·Status: UNKNOWN ·Phase: PHASE1
-
Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
NCT00899080 ·Status: COMPLETED
-
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
NCT05346835 ·Status: AVAILABLE
-
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
NCT06024915 ·Status: COMPLETED ·Phase: PHASE1
-
Prevention of Treatment Induced Neuropathy in Multiple Myeloma
NCT01283997 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
NCT04924608 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3